Literature DB >> 27300115

Use of the Menopause-Specific Quality of Life (MENQOL) questionnaire in research and clinical practice: a comprehensive scoping review.

Beate C Sydora1, Hilary Fast, Sandy Campbell, Nese Yuksel, Jacqueline E Lewis, Sue Ross.   

Abstract

OBJECTIVE: The Menopause-Specific Quality of Life (MENQOL) questionnaire was developed as a validated research tool to measure condition-specific QOL in early postmenopausal women. We conducted a comprehensive scoping review to explore the extent of MENQOL's use in research and clinical practice to assess its value in providing effective, adequate, and comparable participant assessment information.
METHODS: Thirteen biomedical and clinical databases were systematically searched with "menqol" as a search term to find articles using MENQOL or its validated derivative MENQOL-Intervention as investigative or clinical tools from 1996 to November 2014 inclusive. Review articles, conference abstracts, proceedings, dissertations, and incomplete trials were excluded. Additional articles were collected from references within key articles. Three independent reviewers extracted data reflecting study design, intervention, sample characteristics, MENQOL questionnaire version, modifications and language, recall period, and analysis detail. Data analyses included categorization and descriptive statistics.
RESULTS: The review included 220 eligible papers of various study designs, covering 39 countries worldwide and using MENQOL translated into more than 25 languages. A variety of modifications to the original questionnaire were identified, including omission or addition of items and alterations to the validated methodological analysis. No papers were found that described MENQOL's use in clinical practice.
CONCLUSIONS: Our study found an extensive and steadily increasing use of MENQOL in clinical and epidemiological research over 18 years postpublication. Our results stress the importance of proper reporting and validation of translations and variations to ensure outcome comparison and transparency of MENQOL's use. The value of MENQOL in clinical practice remains unknown.

Entities:  

Mesh:

Year:  2016        PMID: 27300115     DOI: 10.1097/GME.0000000000000636

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  11 in total

1.  [Validity and Reliability of the Korean Version of the Menopause-Specific Quality of Life].

Authors:  Jin Hee Park; Sun Hyoung Bae; Young Mi Jung
Journal:  J Korean Acad Nurs       Date:  2020-06       Impact factor: 0.984

2.  Psychometric properties of the Menopause Specific Quality of Life questionnaire among Thai women with a history of breast cancer.

Authors:  Warunee Phligbua; Ellen M Lovie Smith; Debra L Barton
Journal:  Eur J Oncol Nurs       Date:  2018-08-25       Impact factor: 2.398

3.  Describing the status of reproductive ageing simply and precisely: A reproductive ageing score based on three questions and validated with hormone levels.

Authors:  Kai Triebner; Ane Johannessen; Cecilie Svanes; Bénédicte Leynaert; Bryndís Benediktsdóttir; Pascal Demoly; Shyamali C Dharmage; Karl A Franklin; Joachim Heinrich; Mathias Holm; Deborah Jarvis; Eva Lindberg; Jesús Martínez Moratalla Rovira; Nerea Muniozguren Agirre; José Luis Sánchez-Ramos; Vivi Schlünssen; Svein Magne Skulstad; Steinar Hustad; Francisco J Rodriguez; Francisco Gómez Real
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

4.  Quality of life in climacteric women assisted by primary health care.

Authors:  Geraldo Edson Souza Guerra; Antônio Prates Caldeira; Fernanda Piana Santos Lima de Oliveira; Maria Fernanda Santos Figueiredo Brito; Kelma Dayana de Oliveira Silva Gerra; Carlos Eduardo Mendes D'Angelis; Luís Antônio Nogueira Dos Santos; Lucineia de Pinho; Josiane Santos Brant Rocha; Daniela Araújo Veloso Popoff
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

5.  Menopause experience in First Nations women and initiatives for menopause symptom awareness; a community-based participatory research approach.

Authors:  Beate C Sydora; Bonny Graham; Richard T Oster; Sue Ross
Journal:  BMC Womens Health       Date:  2021-04-26       Impact factor: 2.809

6.  Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study.

Authors:  S E Aapkes; L H P Bernts; A P van den Berg; M van den Berg; H Blokzijl; A E P Cantineau; M D A van Gastel; R J de Haas; P Kappert; R U Müller; F Nevens; R Torra; A Visser; J P H Drenth; R T Gansevoort
Journal:  BMC Gastroenterol       Date:  2022-02-25       Impact factor: 3.067

7.  Ideal Cardiovascular Health Metrics and Risk of Incident Early-Onset Vasomotor Symptoms Among Premenopausal Women.

Authors:  Hye Rin Choi; Yoosoo Chang; Yejin Kim; Yoosun Cho; Jeonggyu Kang; Min-Jung Kwon; Ria Kwon; Ga-Young Lim; Kye-Hyun Kim; Hoon Kim; Yun Soo Hong; Jihwan Park; Di Zhao; Juhee Cho; Eliseo Guallar; Hyun-Young Park; Seungho Ryu
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

8.  High low-density lipoprotein cholesterol level is associated with an increased risk of incident early-onset vasomotor symptoms.

Authors:  Hye Rin Choi; Yoosoo Chang; Yejin Kim; Jeonggyu Kang; Min-Jung Kwon; Ria Kwon; Ga-Young Lim; Kye-Hyun Kim; Hoon Kim; Yun Soo Hong; Di Zhao; Juhee Cho; Eliseo Guallar; Hyun-Young Park; Seungho Ryu
Journal:  Sci Rep       Date:  2022-08-27       Impact factor: 4.996

9.  Effects of Phytoestrogen Supplement on Quality of Life of Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Ching-Ching Peng; Chia-Yu Liu; Nai-Rong Kuo; Tao-Hsin Tung
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-01       Impact factor: 2.629

10.  Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis.

Authors:  X T Li; P Y Li; Y Liu; H S Yang; L Y He; Y G Fang; J Liu; B Y Liu; J E Chaplin
Journal:  Qual Life Res       Date:  2019-10-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.